STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics (NASDAQ: LKFT) repurchases 83,530 shares in June buyback

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reports progress under its share repurchase program announced on June 9, 2026. The company bought back 83,530 ordinary shares on Euronext Amsterdam between June 22 and June 26, 2026 for a total of €2,108,045.52, at an average price of €25.24 per share.

As of market close on June 26, 2026, Lakefront holds 199,734 of its own ordinary shares. The Belgium-based biotechnology company, formerly known as Galapagos, continues to build a clinical-stage portfolio in immunology and inflammation, including its BCMAxCD3 T-cell engager candidate gamgertamig.

Positive

  • None.

Negative

  • None.
Shares repurchased 83,530 shares Repurchased between June 22–26, 2026
Total buyback amount €2,108,045.52 Cost of 83,530 shares repurchased
Average repurchase price €25.24 per share Weighted average over June 22–26, 2026
Treasury shares held 199,734 shares Own shares held as of June 26, 2026
Shares bought 22/06/2026 15,297 shares at €24.59 Daily repurchases on XAMS
Shares bought 24/06/2026 18,944 shares at €25.55 Daily repurchases on XAMS
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
regulated information regulatory
"Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information"
BCMAxCD3 T-cell engager technical
"anchored by gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager for autoimmune diseases"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Form 20-F regulatory
"including in our most recent annual report on Form 20-F filed with the SEC"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On June 30, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated June 30, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: June 30, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 30 June 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 83,530 Lakefront shares between 22 June 2026 and 26 June 2026, as follows:

Date of purchaseMarket/MTFNumber of sharesAverage price paid (€)Total (€)Lowest price paid (€)Highest price paid (€)
22/06/2026XAMS15,29724.59376,162.4124.3824.96
23/06/2026XAMS15,05025.32381,076.5325.0625.52
24/06/2026XAMS18,94425.55483,992.6825.3025.78
25/06/2026XAMS17,23925.41438,065.4025.1225.72
26/06/2026XAMS17,00025.22428,748.5024.9425.82
Total 83,53025.242,108,045.5224.3825.82

As of market close on 26 June 2026, Lakefront holds 199,734 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

FAQ

What did Lakefront Biotherapeutics (LKFT) announce in its June 2026 Form 6-K?

Lakefront Biotherapeutics reported recent share buybacks under its repurchase program. It repurchased 83,530 shares on Euronext Amsterdam between June 22 and June 26, 2026, reflecting ongoing execution of its previously announced capital allocation plan.

How many Lakefront Biotherapeutics shares were repurchased and at what cost?

The company repurchased 83,530 ordinary shares for a total of €2,108,045.52. The average price paid was €25.24 per share, based on daily purchases executed on Euronext Amsterdam during the June 22–26, 2026 period.

How many treasury shares does Lakefront Biotherapeutics (LKFT) now hold?

As of market close on June 26, 2026, Lakefront holds 199,734 of its own ordinary shares. This figure reflects cumulative buybacks completed to that date under its share repurchase activities disclosed in regulated information releases.

On which market did Lakefront execute its June 2026 share repurchases?

Lakefront executed the June 22–26, 2026 repurchases on Euronext Amsterdam, indicated as XAMS. Each trading day’s number of shares, average price, and price range were disclosed to provide transparency on the execution of the buyback program.

What business focus does Lakefront Biotherapeutics highlight in this release?

Lakefront describes itself as a biotechnology company focused on serious diseases with high unmet need. It emphasizes a clinical-stage portfolio in immunology and inflammation, led by gamgertamig, a potential first-in-class BCMAxCD3 T-cell engager for autoimmune diseases.

Does Lakefront Biotherapeutics include forward-looking statements in this update?

Yes. The company notes that the press release contains forward-looking statements, including about plans to repurchase its ordinary shares. It cautions that actual results may differ due to various risks outlined in its SEC filings, such as its latest Form 20-F.

Filing Exhibits & Attachments

1 document

Press Releases